The role of lactoferrin and tyndallized Lactobacilli in the eradication of opportunistic pathogens and the restoration of vaginal eubiosis

DOI

https://dx.doi.org/10.18565/aig.2025.218

Dikke G.B., Voroshilina E.S.
1) F.I. Inozemtsev Academy of Medical Education, St. Petersburg, Russia; 2) Ural State Medical University, Ministry of Health of Russia, Yekaterinburg, Russia

Objective: To present the results of the use of lactoferrin and tyndallized probiotics (Lactobacillus spp.) as new strategies to fight bacterial and fungal vulvovaginal infections.
Materials and methods: The literature search was conducted in the international databases PubMed/MEDLINE, Google Scholar, Cochrane Library, and the Russian platform eLibrary using the keywords. The search depth was 10 years. The analysis included 46 publications.
Results: Lactoferrin (LF) is a biglobular protein that belongs to the transferrin family and is able to sequester iron necessary for the vital activity of bacteria. This property makes LF an effective antibacterial agent. LF has prebiotic activity and has immunotropic, anti-inflammatory and regenerative effects. Both in vitro and in vivo studies showed that tyndallized probiotic bacteria, their cell-free supernatants and purified key components obtained by heat treatment, are able to protect against pathogens, maintain the integrity of the epithelial barrier, and have an immunomodulatory effect. DuoLact is a combination of tyndallized L. casei and L. acidophilus. LF and DuoLact are part of the DERMOLIVO product line. The vaginal use of medications based on LF and tyndallized Lactobacilli has been tested in several clinical studies and has proven to be highly effective in eradicating opportunistic pathogens that cause vulvovaginal infections and in restoring vaginal eubiosis.
Conclusion: Experimental and clinical studies indicate that lactoferrin and tyndallized Lactobacilli have antibacterial and protective properties and can be used as an additional therapy for vulvovaginal infections.

Authors’ contributions: Dikke G.B., Voroshilina E.S. – developing the concept and design of the study, search for literary sources, writing and editing the article. Both authors contributed equally to the writing of the article.
Conflicts of interest: The authors declare the absence of obvious and potential conflicts of interest related to the publication of this article.
Funding: The article is the result of the authors’ research and initiative. The publication of the article was supported by the Pentcroft Pharma, Moscow, Russia.
For citation: Dikke G.B., Voroshilina E.S. The role of lactoferrin and tyndallized Lactobacilli in the eradication of opportunistic pathogens and the restoration of vaginal eubiosis.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2025; (8): 37-46 (in Russian)
https://dx.doi.org/10.18565/aig.2025.218

vaginal dysbacteriosis

recurrent vulvovaginal infections

bacterial vaginosis

candidal vulvovaginitis

lactoferrin

Lactobacilli

tyndallized probiotics

Full text (in Russian)

Muzny C.A., Łaniewski P., Schwebke J.R., Herbst-Kralovetz M.M. Host-vaginal microbiota interactions in the pathogenesis of bacterial vaginosis. Curr. Opin. Infect. Dis. 2020; 33(1): 59-65. https://dx.doi.org/10.1097/QCO.0000000000000620
Ma X., Wu M., Wang C., Li H., Fan A., Wang Y. et al. The pathogenesis of prevalent aerobic bacteria in aerobic vaginitis and adverse pregnancy outcomes: a narrative review. Reprod. Health. 2022; 19(1): 21. https://dx.doi.org/10.1186/s12978-021-01292-8
Jahic M. Aerobic vaginitis caused by Enterococcus Faecalis – clinical features and treatment. Mater. Sociomed. 2022; 34(4): 291-5. https://dx.doi.org/10.5455/msm.2022.34.291-295
Blostein F., Levin-Sparenberg E., Wagner J., Foxman B. Recurrent vulvovaginal candidiasis. Ann. Epidemiol. 2017; 27(9): 575-82e. https://dx.doi.org/10.1016/j.ajog.2015.06.067
Foxman B., Muraglia R., Dietz J.P., Sobel J.D., Wagner J. Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. J. Low. Genit. Tract Dis. 2013; 17(3): 340-5. https://dx.doi.org/10.1097/LGT.0b013e318273e8cf
Kalia N., Singh J., Kaur M. Microbiota in vaginal health and pathogenesis of recurrent vulvovaginal infections: a critical review. Ann. Clin. Microbiol. Antimicrob. 2020; 19(1): 5. https://dx.doi.org/10.1186/s12941-020-0347-4
Пунченко О.Е., Березницкая Е.А., Ермоленко Е.И. Микробиота женских половых органов: норма, патология, пути коррекции. Акушерство и гинекология. 2021; 3: 18-24. [Punchenko O.E., Bereznitskaya E.A., Ermolenko E.I. Microbiota of the female genital organs: norm, pathology, and correction methods. Obstetrics and Gynecology. 2021; (3): 18-24 (in Russian)]. https://dx.doi.org/10.18565/aig.2021.3.18-24
Belayneh M., Sehn E., Korownyk C. Recurrent vulvovaginal candidiasis. Can. Fam. Physician. 2017; 63(6): 455.
Yang S., Zhang Y., Liu Y., Wang J., Chen S., Li S. Clinical significance and characteristic clinical differences of cytolytic vaginosis in recurrent vulvovaginitis. Gynecol. Obstet. Invest. 2017; 82(2): 137-43. https://dx.doi.org/10.1159/000446945
Sobel J.D., Kaur N., Woznicki N.A., Boikov D., Aguin T., Gill G. et al. Prognostic indicators of recurrence of bacterial vaginosis. J. Clin. Microbiol. 2019; 57(5): e00227-19. https://dx.doi.org/10.1128/JCM.00227-19
Mollin A., Katta M., Sobel J.D., Akins R.A. Association of key species of vaginal bacteria of recurrent bacterial vaginosis patients before and after oral metronidazole therapy with short- and long-term clinical outcomes. PLOS One. 2022; 17(7): e0272012. https://dx.doi.org/10.1371/journal.pone.0272012
Turner E., Sobel J.D., Akins R.A. Prognosis of recurrent bacterial vaginosis based on longitudinal changes in abundance of Lactobacillus and specific species of Gardnerella. PLOS One. 2021; 16(8): e0256445. https://dx.doi.org/10.1371/journal.pone.0256445
Uddin T.M., Chakraborty A.J., Khusro A., Zidan B.R.M., Mitra S., Emran T.B. et al. Antibiotic resistance in microbes: history, mechanisms, therapeutic strategies and future prospects. J. Infect. Public. Health. 2021; 14(12): 1750-66. https://dx.doi.org/10.1016/j.jiph.2021.10.020
Hashemi S.E., Shokohi T., Abastabar M., Aslani N., Ghadamzadeh M., Haghani I. Species distribution and susceptibility profiles of Candida species isolated from vulvovaginal candidiasis, emergence of C. lusitaniae. Curr. Med. Mycol. 2019; 5(4): 26-34. https://dx.doi.org/10.18502/cmm.5.4.2062
O’Neill J. Tackling drug-resistant infections globally: final report and recommendations. The review on antimicrobial resistance. London, UK: HM Government and the Wellcome Trust. [Internet]; Wellcome Trust, 2016. 80 p. Available at: https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf
Abavisani M., Sahebi S., Dadgar F., Peikfalak F., Keikha M. The role of probiotics as adjunct treatment in the prevention and management of gynecological infections: an updated meta-analysis of 35 RCT studies. Taiwan. J. Obstet. Gynecol. 2024; 63(3): 357-68. https://dx.doi.org/10.1016/j.tjog.2024.03.004
Malfa P., Brambilla L., Giardina S., Masciarelli M., Squarzanti D.F., Carlomagno F. et al. Evaluation of antimicrobial, antiadhesive and co-aggregation activity of a multi-strain probiotic composition against different urogenital pathogens. Int. J. Mol. Sci. 2023; 24(2): 1323. https://dx.doi.org/10.3390/ijms24021323
Swidsinski A., Guschin A., Tang Q., Dörffel Y., Verstraelen H., Tertychnyy A. et al. Vulvovaginal candidiasis: histologic lesions are primarily polymicrobial and invasive and do not contain biofilms. Am. J. Obstet. Gynecol 2019; 220: 91.e1-8. https://dx.doi.org/10.1016/j.ajog.2018.10.023
McKloud E., Delaney C., Sherry L., Kean R., Williams S., Metcalfe R. et al. Recurrent vulvovaginal candidiasis: a dynamic interkingdom biofilm disease of Candida and Lactobacillus. mSystems. 2021; 6(4): e0062221. https://dx.doi.org/10.1128/mSystems.00622-21
Parolin C., Croatti V., Giordani B., Vitali B. Vaginal Lactobacillus impair Candida dimorphic switching and biofilm formation. Microorganisms. 2022; 10(10): 2091. https://dx.doi.org/10.3390/microorganisms10102091
Amabebe E., Anumba D.O.C. The vaginal microenvironment: the physiologic role of Lactobacilli. Front. Med. (Lausanne). 2018; 5: 181. https://dx.doi.org/10.3389/fmed.2018.00181
Van de Wijgert J., Verwijs M.C. Lactobacilli-containing vaginal probiotics to cure or prevent bacterial or fungal vaginal dysbiosis: a systematic review and recommendations for future trial designs. BJOG. 2020; 127(2): 287-99. https://dx.doi.org/10.1111/1471-0528.15870
Gonciarz R.L., Renslo A.R. Emerging role of ferrous iron in bacterial growth and host-pathogen interaction: new tools for chemical (micro)biology and antibacterial therapy. Curr. Opin. Chem. Biol. 2021; 61: 170-8. https://dx.doi.org/10.1016/j.cbpa.2021.01.015
Chandrangsu P., Rensing C., Helmann J.D. Metal homeostasis and resistance in bacteria. Nat. Rev. Microbiol. 2017; 15(6): 338-50. https://dx.doi.org/10.1038/nrmicro.2017.15
Moreira A.C., Silva T., Mesquita G., Gomes A.C., Bento C.M., Neves J.V. et al. H-ferritin produced by myeloid cells is released to the circulation and plays a major role in liver iron distribution during infection. Int. J. Mol. Sci. 2021; 23(1): 269. https://dx.doi.org/10.3390/ijms23010269
Porcheron G., Dozois C.M. Interplay between iron homeostasis and virulence: Fur and RyhB as major regulators of bacterial pathogenicity. Vet. Microbiol. 2015; 179(1-2): 2-14. https://dx.doi.org/10.1016/j.vetmic.2015.03.024
Artym J., Zimecki M. Antimicrobial and prebiotic activity of lactoferrin in the female reproductive tract: a comprehensive review. Biomedicines. 2021; 9(12): 1940. https://dx.doi.org/10.3390/biomedicines9121940
Valenti P., Rosa L., Capobianco D., Lepanto M.S., Schiavi E., Cutone A. et al. Role of Lactobacilli and Lactoferrin in the mucosal cervicovaginal defense. Front. Immunol. 2018; 9: 376. https://dx.doi.org/10.3389/fimmu.2018.00376
Pino A., Mazza T., Matthews M.H., Castellana S., Caggia C., Randazzo C.L. et al. Antimicrobial activity of bovine lactoferrin against Gardnerella species clinical isolates. Front. Microbiol. 2022; 13: 1000822. https://dx.doi.org/10.3389/fmicb.2022.1000822
Pino A., Giunta G., Randazzo C., Caruso S., Caggia C., Cianci A. Bacterial biota of women with bacterial vaginosis treated with lactoferrin: an open prospective randomized trial. Microb. Ecol. Health Dis. 2017; 28(1): 1357417. https://dx.doi.org/10.1080/16512235.2017.1357417
Sessa R., Di Pietro M., Filardo S., Bressan A., Rosa L., Cutone A. et al. Effect of bovine lactoferrin on Chlamydia trachomatis infection and inflammation. Biochem. Cell. Biol. 2017; 95(1): 34-40. https://dx.doi.org/10.1139/bcb-2016-0049
Liao H., Liu S., Wang H., Su H., Liu Z. Enhanced antifungal activity of bovine lactoferrin-producing probiotic Lactobacillus casei in the murine model of vulvovaginal candidiasis. BMC Microbiol. 2019; 19(1): 7. https://dx.doi.org/10.1186/s12866-018-1370-x
Russo R., Superti F., Karadja E., De Seta F. Randomised clinical trial in women with recurrent vulvovaginal Candidiasis: efficacy of probiotics and lactoferrin as maintenance treatment. Mycoses. 2019; 62(4): 328-35. https://dx.doi.org/10.1111/myc.12883
Rosa L., Cutone A., Conte M.P., Campione E., Bianchi L., Valenti P. An overview on in vitro and in vivo antiviral activity of lactoferrin: its efficacy against SARS-CoV-2 infection. Biometals. 2023; 36(3): 417-36. https://dx.doi.org/10.1007/s10534-022-00427-z
Kaplan M., Baktıroğlu M., Kalkan A.E., Canbolat A.A., Lombardo M., Raposo A. et al. Lactoferrin: a promising therapeutic molecule against Human Papillomavirus. Nutrients. 2024; 16(18): 3073. https://dx.doi.org/10.3390/nu16183073
Gibson G.R., Hutkins R., Sanders M.E., Prescott S.L., Reimer R.A., Salminen S.J. et al. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat. Rev. Gastroenterol. Hepatol. 2017; 14(8): 491-502. https://dx.doi.org/10.1038/nrgastro.2017.75
Liu Z.S., Lin C.F., Chen P.W. Transcriptome analysis of Lactobacillus rhamnosus GG strain treated with prebiotic – bovine lactoferrin under a cold environment. J. Food Drug Anal. 2021; 29(3): 402-18. https://dx.doi.org/10.38212/2224-6614.3369
Chen P.W., Liu Z.S., Kuo T.C., Hsieh M.C., Li Z.W. Prebiotic effects of bovine lactoferrin on specific probiotic bacteria. Biometals. 2017; 30(2): 237-48. https://dx.doi.org/10.1007/s10534-017-9999-8
Vega-Bautista A., de la Garza M., Carrero J.C., Campos-Rodríguez R., Godínez-Victoria M., Drago-Serrano M.E. The impact of lactoferrin on the growth of intestinal inhabitant bacteria. Int. J. Mol. Sci. 2019; 20(19): 4707. https://dx.doi.org/10.3390/ijms20194707
Nader-Macías M.E.F., De Gregorio P.R., Silva J.A. Probiotic lactobacilli in formulas and hygiene products for the health of the urogenital tract. Pharmacol. Res. Perspect. 2021; 9(5): e00787. https://dx.doi.org/10.1002/prp2.787
Russo R., Edu A., De Seta F. Study on the effects of an oral lactobacilli and lactoferrin complex in women with intermediate vaginal microbiota. Arch. Gynecol. Obstet. 2018; 298(1): 139-45. https://dx.doi.org/10.1007/s00404-018-4771-z
Trentini A., Maritati M., Rosta V., Cervellati C., Manfrinato M.C., Hanau S. et al. Vaginal lactoferrin administration decreases oxidative stress in the amniotic fluid of pregnant women: an open-label randomized pilot study. Front. Med. (Lausanne). 2020; 7: 555. https://dx.doi.org/10.3389/fmed.2020.00555
Ali A.E., Fathi M.A., Mohammed A.I. Efficacy of lactoferrin in prevention of premature rupture of membrane. Egypt. J. Hosp. Med. 2021; 85: 2823-7. https://dx.doi.org/10.21608/ejhm.2021.190182
Eker F., Duman H., Ertürk M., Karav S. The potential of lactoferrin as antiviral and immune-modulating agent in viral infectious diseases. Front. Immunol. 2024; 15: 1402135. https://dx.doi.org/10.3389/fimmu.2024.1402135
Superti F., De Seta F. Warding off recurrent yeast and bacterial vaginal Infections: lactoferrin and lactobacilli. Microorganisms. 2020; 8(1): 130. https://dx.doi.org/10.3390/microorganisms8010130
Wang Z., He Y., Zheng Y. Probiotics for the treatment of bacterial vaginosis: a meta-analysis. Int. J. Environ. Res. Public Health. 2019; 16(20): 3859. https://dx.doi.org/10.3390/ijerph16203859
Pytka M., Kordowska-Wiater M., Jarocki P. Microbiome of the women’s genital tract. Adv. Microbiol. 2019; 58: 227-36. https://dx.doi.org/10.21307/PM-2019.58.3.227
Кира Е.Ф., Припутневич Т.В., Кира Е.Е. Биологические и биохимические защитные факторы влагалища и цервикального канала: механизмы стабильности и варианты коррекции. Акушерство и гинекология. 2025; 3: 30-42. [Kira E.F., Priputnevich T.V., Kira E.E. Biological and biochemical protective factors of the vagina and cervical canal: mechanisms of stability and correction options. Obstetrics and Gynecology. 2025; (3): 30-42 (in Russian)]. https://dx.doi.org/10.18565/aig.2025.33
Piqué N., Berlanga M., Miñana-Galbis D. Health benefits of heat-killed (Tyndallized) probiotics: an overview. Int. J. Mol. Sci. 2019; 20(10): 2534. https://dx.doi.org/10.3390/ijms20102534
De Marco S., Sichetti M., Muradyan D., Piccioni M., Traina G., Pagiotti R. et al. Probiotic cell-free supernatants exhibited anti-inflammatory and antioxidant activity on human gut epithelial cells and macrophages stimulated with LPS. Evid. Based Complement. Alternat. Med. 2018; 2: 1-12. https://dx.doi.org/10.1155/2018/1756308
Elughi G.N., Oniha M.I., Obafemi Y.D., Akinyosoye A.D., Ahuekwe E.F., Akinduti P.A. Antibacterial activity of cell-free supernatants of probiotic lactobacillus against bacterial pathogens associated with vaginal infections. J. Pure Appl. Microbiol. 2024; 18(1): 451-9. https://dx.doi.org/10.22207/JPAM.18.1.28
Moon E.C., Park M.S., Lim T., Kim R.H., Ji G.E., Kim S.Y. et al. Antibacterial effect of cell-free supernatant fraction from Lactobacillus paracasei CH88 against Gardnerella vaginalis. Sci. Rep. 2022; 12(1): 4763. https://dx.doi.org/10.1038/s41598-022-08808-7
Scillato M., Spitale A., Mongelli G., Privitera G.F., Mangano K., Cianci A. et al. Antimicrobial properties of Lactobacillus cell-free supernatants against multidrug-resistant urogenital pathogens. Microbiologyopen. 2021; 10(2): e1173. https://dx.doi.org/10.1002/mbo3.1173
Barea B.M., Veeratterapillay R., Harding C. Nonantibiotic treatments for urinary cystitis: an update. Curr. Opin. Urol. 2020; 30(6): 845-52. https://dx.doi.org/10.1097/MOU.0000000000000821
Drumond M.M., Tapia-Costa A.P., Neumann E., Nunes Á.C., Barbosa J.W., Kassuha D.E. et al. Cell-free supernatant of probiotic bacteria exerted antibiofilm and antibacterial activities against Pseudomonas aeruginosa: a novel biotic therapy. Front. Pharmacol. 2023; 14: 1152588. https://dx.doi.org/10.3389/fphar.2023.1152588
Zanetta P., Ballacchino C., Squarzanti D.F., Amoruso A., Pane M., Azzimonti B. Lactobacillus johnsonii LJO02 (DSM 33828) cell-free supernatant and vitamin D improve wound healing and reduce interleukin-6 production in Staphylococcus aureus infected human keratinocytes. Pharmaceutics. 2023; 16(1): 18. https://dx.doi.org/10.3390/pharmaceutics16010018
Gökalp F. An investigation of the olive phenols activity as a natural medicine. J. Food Drug Anal. 2018; 26(2): 657-61. https://dx.doi.org/10.1016/j.jfda.2017.07.003
Di Pietro M., Filardo S., Mattioli R., Francioso A., Raponi G., Mosca L. et al. Extra virgin olive oil-based green formulations with promising antimicrobial activity against drug-resistant isolates. Front. Pharmacol. 2022; 13: 885735. https://dx.doi.org/10.3389/fphar.2022.885735
Bucciantini M., Leri M., Nardiello P., Casamenti F., Stefani M. Olive polyphenols: antioxidant and anti-inflammatory properties. Antioxidants (Basel). 2021; 10(7): 1044. https://dx.doi.org/10.3390/antiox10071044
Lin T.K., Zhong L., Santiago J.L. Anti-inflammatory and skin barrier repair effects of topical application of some plant oils. Int. J. Mol. Sci. 2017; 19(1): 70. https://dx.doi.org/10.3390/ijms19010070
González-Acedo A., Ramos-Torrecillas J., Illescas-Montes R., Costela-Ruiz V.J., Ruiz C., Melguizo-Rodríguez L. et al. The benefits of olive oil for skin health: study on the effect of hydroxytyrosol, tyrosol, and oleocanthal on human fibroblasts. Nutrients. 2023; 15(9): 2077. https://dx.doi.org/10.3390/nu15092077
Sánchez-Quesada C., López-Biedma A., Toledo E., Gaforio J.J. Squalene stimulates a key innate immune cell to foster wound healing and tissue repair. Evid. Based Complement. Alternat. Med. 2018; 2018: 9473094. https://dx.doi.org/10.1155/2018/9473094
Melguizo-Rodríguez L., de Luna-Bertos E., Ramos-Torrecillas J., Illescas-Montesa R., Costela-Ruiz V.J., García-Martínez O. Potential effects of phenolic compounds that can be found in olive oil on wound healing. Foods. 2021; 10(7): 1642. https://dx.doi.org/10.3390/foods10071642
Taheri M., Amiri-Farahani L. Anti-inflammatory and restorative effects of olives in topical application. Dermatol. Res. Pract. 2021; 2021: 9927976. https://dx.doi.org/10.1155/2021/9927976
Harwood A., Nassereddin A., Krishnamurthy K. Moisturizers. 2024 Feb 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.
Miranda M., Saccone G., Ammendola A., Salzano E., Iannicelli M., De Rosa R. et al. Vaginal lactoferrin in prevention of preterm birth in women with bacterial vaginosis. J Matern. Fetal Neonatal. Med. 2021; 34(22): 3704-8. https://dx.doi.org/10.1080/14767058.2019.1690445
D'Amico A., Buca D., Tinari S., Oronzii L., Lucidi A., Di Sebastiano F. et al. Role of lactoferrin in preventing preterm birth and pregnancy complications: a systematic review and meta-analysis. Minerva Obstet. Gynecol. 2023; 75(3): 273-8. https://dx.doi.org/10.23736/S2724-606X.22.05032-1
Juraskova I., Jarvis S., Mok K., Peate M., Meiser B., Cheah B.C. et al. The acceptability, feasibility, and efficacy (phase I/II study) of the OVERcome (Olive Oil, Vaginal Exercise, and MoisturizeR) intervention to improve dyspareunia and alleviate sexual problems in women with breast cancer. J. Sex. Med. 2013; 10(10): 2549-58. https://dx.doi.org/10.1111/jsm.12156
Vale F., Rezende C., Raciclan A., Bretas T., Geber S. Efficacy and safety of a non-hormonal intravaginal moisturizer for the treatment of vaginal dryness in postmenopausal women with sexual dysfunction. Eur. J. Obstet. Gynecol. Reprod. Biol. 2019; 234: 92-5. https://dx.doi.org/10.1016/j.ejogrb.2018.12.040
Archer D.F., Goldstein S.R., Simon J.A., Waldbaum A.S., Sussman S.A., Altomare C. et al. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial. Menopause. 2019; 26(6): 611-21. https://dx.doi.org/10.1097/GME.0000000000001292
Sacarin G., Abu-Awwad A., Razvan N., Craina M., Hogea B., Sorop B. et al. Sexual quality of life in postmenopausal women: a comparative randomized controlled trial of intravaginal PRP therapy versus local hormonal treatments. Medicina (Kaunas). 2025; 61(7): 1140. https://dx.doi.org/10.3390/medicina61071140

Received 15.08.2025

Accepted 21.08.2025

Galina B. Dikke, Dr. Med. Sci., Associate Professor, Professor at the Department of Obstetrics and Gynecology in the Course of Reproductive Medicine, F.I. Inozemtsev Academy of Medical Education, 190013, Russia, St. Petersburg, Moskovsky Ave., 22, letter M, galadikke@yandex.ru, https://orcid.org/0000-0001-9524-8962
Ekaterina S. Voroshilina, Dr. Med. Sci., Professor, Head of the Department of Medical Microbiology and Clinical Laboratory Diagnostics, Ural State Medical University,
Ministry of Health of Russia, 620062, Russia, Sverdlovsk region, Yekaterinburg, Repin str., 3, voroshilina@gmail.com, https://orcid.org/0000-0003-1630-1628
Corresponding author: Galina B. Dikke, galadikke@yandex.ru

The role of lactoferrin and tyndallized Lactobacilli in the eradication of opportunistic pathogens and the restoration of vaginal eubiosis

Dikke G.B., Voroshilina E.S.

Keywords

References

About the Authors

Similar Articles